Lineage Cell Net Worth
Lineage Cell Net Worth Breakdown | LCTX |
Lineage Cell Net Worth Analysis
Lineage Cell's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Lineage Cell's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Lineage Cell's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Lineage Cell's net worth analysis. One common approach is to calculate Lineage Cell's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Lineage Cell's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Lineage Cell's net worth. This approach calculates the present value of Lineage Cell's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Lineage Cell's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Lineage Cell's net worth. This involves comparing Lineage Cell's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Lineage Cell's net worth relative to its peers.
Enterprise Value |
|
To determine if Lineage Cell is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Lineage Cell's net worth research are outlined below:
| Lineage Cell generated a negative expected return over the last 90 days | |
| Lineage Cell has high historical volatility and very poor performance | |
| Lineage Cell has some characteristics of a very speculative penny stock | |
| The company reported the previous year's revenue of 8.95 M. Net Loss for the year was (21.49 M) with profit before overhead, payroll, taxes, and interest of 13.97 M. | |
| Lineage Cell Therapeutics currently holds about 66.36 M in cash with (28.57 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.39. | |
| Lineage Cell has a frail financial position based on the latest SEC disclosures | |
| Latest headline from news.google.com: Lineage Cell Therapeutics stock rating holds at Buy, Phase 2a data sparks target rise - Investing.com |
Lineage Cell Quarterly Good Will |
|
Lineage Cell uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Lineage Cell Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Lineage Cell's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 14th of March 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 14th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Follow Lineage Cell's market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 135.03 M.Market Cap |
|
Project Lineage Cell's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.49) | (0.52) | |
| Return On Capital Employed | (0.30) | (0.31) | |
| Return On Assets | (0.21) | (0.22) | |
| Return On Equity | (0.34) | (0.32) |
When accessing Lineage Cell's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Lineage Cell's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Lineage Cell's profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Lineage Cell's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Lineage Cell Therapeutics. Check Lineage Cell's Beneish M Score to see the likelihood of Lineage Cell's management manipulating its earnings.
Evaluate Lineage Cell's management efficiency
Lineage Cell Therapeutics has return on total asset (ROA) of (0.1286) % which means that it has lost $0.1286 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3504) %, meaning that it created substantial loss on money invested by shareholders. Lineage Cell's management efficiency ratios could be used to measure how well Lineage Cell manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.52 in 2024. Return On Capital Employed is likely to drop to -0.31 in 2024. At this time, Lineage Cell's Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 65.7 M in 2024, whereas Total Current Assets are likely to drop slightly above 21.1 M in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.36 | 0.41 | |
| Tangible Book Value Per Share | 0.03 | 0.03 | |
| Enterprise Value Over EBITDA | (6.48) | (6.80) | |
| Price Book Value Ratio | 2.97 | 3.12 | |
| Enterprise Value Multiple | (6.48) | (6.80) | |
| Price Fair Value | 2.97 | 3.12 | |
| Enterprise Value | 196.7 M | 206.5 M |
Understanding the operational decisions made by Lineage Cell management offers insights into its financial robustness. This evaluation is crucial for assessing the stock's investment potential.
Enterprise Value Revenue 12.0502 | Revenue 6.2 M | Quarterly Revenue Growth (0.56) | Revenue Per Share 0.034 | Return On Equity (0.35) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Lineage Cell insiders, such as employees or executives, is commonly permitted as long as it does not rely on Lineage Cell's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Lineage Cell insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Samuel George A. Iii over two weeks ago Acquisition by Samuel George A. Iii of 15000 shares of Lineage Cell at 0.6 subject to Rule 16b-3 | ||
Mulroy Michael H. over two weeks ago Acquisition by Mulroy Michael H. of 40000 shares of Lineage Cell at 0.566 subject to Rule 16b-3 | ||
Hogge Gary S. over three months ago Disposition of 5310 shares by Hogge Gary S. of Lineage Cell at 1.35 subject to Rule 16b-3 | ||
Jill Howe over three months ago Acquisition by Jill Howe of 10500 shares of Lineage Cell at 0.89 subject to Rule 16b-3 | ||
Bradsher Neal C over three months ago Acquisition by Bradsher Neal C of 75000 shares of Lineage Cell at 0.9541 subject to Rule 16b-3 | ||
Culley Brian M over six months ago Acquisition by Culley Brian M of 10000 shares of Lineage Cell at 1.05 subject to Rule 16b-3 | ||
Jill Howe over six months ago Acquisition by Jill Howe of 650000 shares of Lineage Cell at 1.13 subject to Rule 16b-3 | ||
West Michael D over a year ago Payment of 587 shares by West Michael D of Lineage Cell subject to Rule 16b-3 |
Lineage Cell Earnings per Share Projection vs Actual
Lineage Cell Corporate Management
| Charlotte Hubbert | Vice Development | Profile | |
| Jill Howe | CFO Officer | Profile | |
| DVM Dvm | VP Affairs | Profile | |
| Alexandra Hernandez | Senior Controller | Profile | |
| JD III | General Secretary | Profile | |
| Ioana Hone | Director Relations | Profile |
Additional Tools for Lineage Stock Analysis
When running Lineage Cell's price analysis, check to measure Lineage Cell's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lineage Cell is operating at the current time. Most of Lineage Cell's value examination focuses on studying past and present price action to predict the probability of Lineage Cell's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lineage Cell's price. Additionally, you may evaluate how the addition of Lineage Cell to your portfolios can decrease your overall portfolio volatility.